ABSTRACT
Regadenoson is a widely used and well-tolerated vasodilator agent for pharmacologic stress myocardial perfusing imaging. In patients at higher risk of adverse reactions such as those with end stage renal disease, it can be reversed with early administration of aminophylline. However, little is known about late administration of aminophylline. This case report describes the efficacy of late aminophylline use in patients with end stage renal disease. Possible explanations for the prolonged pharmacodynamic effect of regadenoson in this group are discussed.
ABSTRACT
Positron emission tomography (PET) offers the unique capability of measuring non-invasive by the regional myocardial substrate flow and the biochemical reaction index in millimol per minute per gram of myocardial tissue. PET also allows for the assessment or quantification of regional myocardial blood flow, cardiac metabolism, ventricular function, myocardial viability, as well as autonomous nervous system, research and evaluating of dilated myocardiopathy and of ventricular hypertrophy. PET's success is based on the radioisotopes properties, their very short half-life allows for the administration of large doses.
